CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 501–600 of 1,725
GL67 lipid-based liposomal formulation for efficient siRNA delivery into human lung cancer cells
Jarallah, S. J., Aldossary, A. M., Tawfik, E. A., Altamimi, R. M., Alsharif, W. K., Alzahrani, N. M., Sobeai, H. M. A., Qamar, W., Alfahad, A. J., Alshabibi, M. A., et al. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.05.017 · Cited by 24
Neldeborg, S., Soerensen, J. F., Møller, C. T., Bill, M., Gao, Z., Bak, R. O., Holm, K., Sørensen, B. S., Nyegaard, M., Luo, Y., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01950-9 · Cited by 22
“Another delivery strategy, lipid nanoparticles, have been shown to instigate a low immune response potentially allowing for repeated treatment cycles with CRISPR-Cas9 [25, 45].”
BackgroundPalanki, R., Han, E. L., Murray, A. M., Maganti, R., Tang, S. N., Swingle, K. L., Kim, D., Yamagata, H. M., Safford, H. C., Mrksich, K., et al. (2024) · Lab on a Chip · doi:10.1039/d4lc00283k · Cited by 25
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy
Planté‐Bordeneuve, V., & Perrain, V. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306843 · Cited by 23
“The CRISPR-Cas9 system is a recent breakthrough technology that permits targeted genome editing in vivo [54].”
BackgroundCRISPR/Cas systems combined with DNA nanostructures for biomedical applications
Sun, S., Yang, H., Wu, Z., Zhang, S., Xu, J., & Shi, P. (2024) · Chemical Communications · doi:10.1039/d4cc00290c · Cited by 23
Meng, X., Jia, R., Zhao, X., Zhang, F., Chen, S., Yu, S., Liu, X., Dou, H., Feng, X., Zhang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48092-9 · Cited by 33
“The fi rst CRISPR/ Cas9-based in vivo gene editing (product NTLA-2001) for Transthyr-oidosis Amyloidosis has also been reported subsequently 42 .”
Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment
Vogel, J. K., Carpinteiro, A., Luedike, P., Buehning, F., Wernhart, S., Rassaf, T., & Michel, L. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00669-7 · Cited by 27
Tashima, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020201 · Cited by 22
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.016 · Cited by 31
Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy
Griffin, J. M., Grodin, J. L., Ruberg, F. L., Masri, A., Hanna, M. A., & Maurer, M. S. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.017 · Cited by 32
Shuvaev, V. V., Tam, Y. K., Lee, B. W., Myerson, J. W., Herbst, D. A., Kiseleva, R. Y., Glassman, P. M., Parhiz, H., Alameh, M., Pardi, N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409266122 · Cited by 27
Musolino, P. L., Rosser, S. J., Brittan, M., Newby, D. E., Berry, C., Riley, P. R., Giacca, M., Hajjar, R. J., & Baker, A. H. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf109 · Cited by 26
“39 The development of LDL receptor independent delivery using the GalNAC lipid nanoparticles technology has enabled both delivery of genome editors to patients with intact LDL receptor activity as well as to those afflicted by homozygous familial hypercholesterolaemia.”
Genetics of Kidney Disease: The Unexpected Role of Rare Disorders
Elliott, M. D., Rasouly, H. M., & Gharavi, A. G. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-101813 · Cited by 24
Transient and tunable CRISPRa regulation of APOBEC/AID genes for targeting hepatitis B virus
Kostyushev, D. S., Brezgin, S. A., Kostyusheva, A. P., Ponomareva, N. I., Олеговна, Б. Е., Zakirova, N. F., Kondrashova, A., Goptar, I. A., Nikiforova, A., Sudina, A., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.016 · Cited by 24
“So far, only gene editing approaches have successfully managed to achieve long-term functional benefits.(47) Whether transient delivery of CRISPRa in the form of short-lived RNPs can be used in a therapeutic context is so far unclear.”
BackgroundCRISPR/Cas9 for hepatitis B virus infection treatment
Cai, B., Chang, S., Tian, Y., & Zhen, S. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.866 · Cited by 21
“The persistence of knockout effect by expressing HBV targeted sequence is a very useful feature in the treatment of chronic diseases.(48,49) However, before this method is transformed into clinical application, it is necessary to successfully promote the technology to realize the cheap production of virus vector and a…”
MethodGene therapy for heart failure and cardiomyopathies
Argirò, A., Ding, J., & ADLER, E. D. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.06.009 · Cited by 35
“47,48”
Taharabaru, T., Kihara, T., Obata, A., Onodera, R., Wen, Y., Li, J., Motoyama, K., & Higashi, T. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121443 · Cited by 22
Yao, J., Atasheva, S., Wagner, N. J., Paolo, N. C. D., Stewart, P. L., & Shayakhmetov, D. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.023 · Cited by 23
Molecular Therapeutics in Development to Treat Alzheimer’s Disease
Tartaglia, M. C., & Ingelsson, M. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00738-6 · Cited by 25
Polymeric nanocarriers for therapeutic gene delivery
Zhang, J., Yang, X., Chang, Z., Zhu, W., Ma, Y., & He, H. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101015 · Cited by 51
Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies
Patel, A. G., Li, P.-Y., Badrish, N., Kesari, A., & Shah, K. B. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02172-w · Cited by 20
“A with hATTR-PN with three patients in each of the initial groups (0.1 mg/kg and 0.3 mg/kg) as part of the ongoing trial [20].”
InfluentialTissue Specific DNA Repair Outcomes Shape the Landscape of Genome Editing
Meyenberg, M., da Silva, J. F., & Loizou, J. I. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.728520 · Cited by 22
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 23
Cruz, L. J., Rezaei, S., Grosveld, F. G., Philipsen, S., & Eich, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1030285 · Cited by 25
“Recent publications have demonstrated that specific targeting can be achieved in vivo (Wei et al., 2020; Gillmore et al., 2021; Musunuru et al., 2021; Rothgangl et al., 2021; Mullard, 2022).”
BackgroundThe treatment of amyloidosis is being refined
Cantone, A. F., Sanguettoli, F., Passo, B. D., Serenelli, M., & Rapezzi, C. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac104 · Cited by 24
“Considering this, Gillmore et al.26 performed a Phase I trial on subjects suffering from TTRv polyneuropathy not previously treated with gene silencers, in which there was a significant reduction in serum TTR following a single administration.”
Ma, T., Chen, X., & Wang, M. (2023) · ChemBioChem · doi:10.1002/cbic.202200801 · Cited by 24
CRISPR gene-editing therapies for hypertrophic cardiomyopathy
Strong, A. (2023) · Nature Medicine · doi:10.1038/s41591-022-02184-5 · Cited by 24
A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0776 · Cited by 21
Suzuki, Y., Katsurada, Y., & Hyodo, K. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00547 · Cited by 24
Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts
Dratch, L., Azage, M., Baldwin, A., Johnson, K., Paul, R., Bardakjian, T., Michon, S.-C., Amado, D. A., Baer, M., Deik, A., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12058-6 · Cited by 24
“Several other clinical trials are ongoing, using these same therapeutic strategies as well as antibodies targeting misfolded tran-sthyretin (NCT03336580) and CRISPR/Cas9 gene editing (NCT04601051) [54].”
Strategies for enhanced gene delivery to the central nervous system
Gao, Z. (2024) · Nanoscale Advances · doi:10.1039/d3na01125a · Cited by 29
Molecular mechanisms and therapeutic strategies for neuromuscular diseases
Zambon, A. A., Falzone, Y., Bolino, A., & Previtali, S. C. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05229-9 · Cited by 26
“Hereditary amyloidosis resulting from mutations in the TTR gene (hATTR) is a rare, progressively debilitating, and potentially life-threatening autosomal dominant multi-system disorder [124].”
BackgroundGive Cas a Chance: An Actionable Path to a Platform for CRISPR Cures
Urnov, F. D. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0082 · Cited by 21
Treatment of transthyretin cardiac amyloidosis
Bampatsias, D., Wardhere, A., & Maurer, M. S. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001156 · Cited by 21
“and phase II and III trials are underway ALXN2220 ALXN2220 (formerly NI006) is a recombinant human anti-ATTR monoclonal IgG1 antibody that selectively binds TTR amyloid deposits, but not to normal tetrameric TTR [ .”
Shankar, B., Yanek, L. R., Jefferson, A., Jani, V., Brown, E. E., Tsottles, D., Barranco, J., Zampino, S., Ranek, M. J., Sharma, K., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.05.001 · Cited by 25
AAV-mediated gene therapies by miniature gene editing tools
Kong, X., Li, T., & Yang, H. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2608-5 · Cited by 20
“On the other hand, the clinical trial NTLA-2001, which utilizes LNP delivery, has undergone evaluation for its efficacy in treating polyneuropathic hereditary transthyretin (hATTR) amyloidosis (Gillmore et al., 2021).”
Bates, S. M., Munson, M. J., Trovisco, V., Pereira, S. G. T., Miller, S. R., Sabirsh, A., Betts, C. J., Blenke, E. O., & Gay, N. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114047 · Cited by 31
Wang, C., Pan, Q., Chen, S., Zhang, Y., Xu, X., Yan, X., Guo, J., Chen, X., Li, B., Ganzorig, C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08376 · Cited by 25
In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery
Jozić, A., Roux, C. L., Kim, J., Berchel, M., Sahel, D. K., Bodi, E., Palumbo, M., Vasudevan, A., Murthy, N. T. V., Eygeris, Y., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03022-6 · Cited by 36
Quadruple pegRNA enables programmable and efficient large genomic insertion
Shi, Y.-J., Ding, Z.-Y., Wu, Y., He, Z., Zhang, Y., Zhang, Y.-L., Zhang, Y.-M., Huang, X., Yin, H., & Zhang, Y. (2026) · Nature · doi:10.1038/s41586-026-10395-w · Cited by 27
“Although base editors and prime editors (PEs) have shown promise in correcting pathogenic mutations 1,7–10 , their clinical application is constrained by the rarity and diversity of individual mutations.”
Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
Janowski, M., Milewska, M., Zare, P., & Pękowska, A. (2021) · Pharmaceuticals · doi:10.3390/ph14080765 · Cited by 23
The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 27
“Results showed mild adverse effects, and the administration led to a decrease in TTR after a single dose [199].”
BackgroundLu, Y., Mbakam, C. H., Song, B., Bendavid, E., & Tremblay, J. P. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.892769 · Cited by 24
“Recently, another study prepared NTLA-2001, an in vivo geneediting therapeutic agent, made by lipid nanoparticles encapsulating messenger RNA of Cas9 protein and single guide RNA targeting misfolding transthyretin (TTR) responsible of transthyretin amyloidosis.”
BackgroundLee, J. H., Oh, H.-K., Choi, B. S., Lee, H. H., Lee, K. J., Kim, U. G., Lee, J., Lee, H.-R., Lee, G. S., Ahn, S. J., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.002 · Cited by 19
“proposed in Investigational New Drug applications for recently entered clinical trials targeting blindness and inherited liver disease.(6,42) The advantage of the specificity of CjCas9 could be critical in AAV application, which generally expresses Cas9 over a longterm period, thereby increasing the risk of off-target…”
Lokras, A. G., Chakravarty, A., Rades, T., Christensen, D., Franzyk, H., Thakur, A., & Foged, C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122171 · Cited by 23
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
Mukherjee, P., Park, S. H., Pathak, N., Patino, C. A., Bao, G., & Espinosa, H. D. (2022) · ACS Nano · doi:10.1021/acsnano.2c05494 · Cited by 21
Multiplexed engineering and precision gene editing in cellular immunotherapy
Biederstädt, A., Manzar, G. S., & Daher, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063303 · Cited by 20
In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations
Psatha, N., Paschoudi, K., Παπαδοπούλου, Α., & Yannaki, E. (2022) · Genes · doi:10.3390/genes13122222 · Cited by 25
T Cell Nrf2/Keap1 Gene Editing Using CRISPR/Cas9 and Experimental Kidney Ischemia-Reperfusion Injury
Kurzhagen, J. T., Noel, S., Lee, K., Sadasivam, M., Gharaie, S., Ankireddy, A., Lee, S. A., Newman-Rivera, A. M., Gong, J., Arend, L. J., et al. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0058 · Cited by 19
“In vivo gene editing using CRISPR/Cas9 technology has already successfully been performed in clinical trials for other diseases, and would allow for bypassing obstacles such as electroporation, cell death, and adequate T cell expansion (Gillmore et al., 2021).”
Liu, X., Qiao, J., Jia, R., Zhang, F., Meng, X., Li, Y., & Yang, L. (2023) · eLife · doi:10.7554/elife.84065 · Cited by 21
“, 2021) and transthyretin amyloidosis (Gillmore et al., 2021), and even cancer (Stadtmauer et al.”
BackgroundSpacer Fidelity Assessments of Guide RNA by Top-Down Mass Spectrometry
Macias, L. A., Garcia, S. P., Back, K. M., Wu, Y., Johnson, G. H., Kathiresan, S., Bellinger, A. M., Rohde, E., Freitas, M. A., & Madsen, J. A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00289 · Cited by 22
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Chen, Y., Luo, X. L., Kang, R., Cui, K., Ou, J., Zhang, X., & Liang, P. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.07.007 · Cited by 25
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo
Bestas, B., Wimberger, S., Degtev, D., Madsen, A., Rottner, A. K., Karlsson, F. H., Naumenko, S., Callahan, M., Touza, J. L., Francescatto, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41240-7 · Cited by 20
“Due to its performance and well-characterized nature, SpCas9 was recently advanced into the fi rst human genome editing clinical trial to treat a hereditary disease 11 , with additional trials following soon after 12 – 15 .”
Haase, F., Pöhmerer, J., Yazdi, M., Grau, M., Zeyn, Y., Wilk, U., Burghardt, T., Höhn, M., Hieber, C., Bros, M., et al. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.11.025 · Cited by 25
Li, B., Li, Q., Qi, Z., Li, Z., Yan, X., Chen, Y., Xu, X., Pan, Q., Chen, Y., Huang, F., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202316323 · Cited by 21
Hellenbart, E. L., Ipema, H. J., Ziccardi, M. R., Krishna, H., & DiDomenico, R. J. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4639 · Cited by 24
Base editing as a genetic treatment for spinal muscular atrophyPreprint
Alves, C. R. R., Ha, L. L., Yaworski, R., Lazzarotto, C. R., Christie, K. A., Reilly, A., Beauvais, A., Doll, R. M., de la Cruz, D., Maguire, C. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.20.524978 · Cited by 20
“Early indications from clinical trials utilizing genome editing technologies to treat other diseases indicate that one-time persistent treatments may be within reach 68,69 .”
Woodward, E., Wang, E., Wallis, C. J. D., Sharma, R. K., Tie, A. W. J., Murthy, N., & Blancafort, P. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4051-7_14 · Cited by 19
Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations
Chaugule, S. R., Constantinou, C. K., John, A. A., Micha, D., Eekhoff, E. M. W., Gravallese, E. M., Gao, G., & Shim, J. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.191 · Cited by 30
Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses
Huayamares, S. G., Lian, L., Rab, R., Hou, Y., Radmand, A., Kim, H., Zenhausern, R., Achyut, B. R., Gilbert‐Ross, M., Lokugamage, M. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58548-1 · Cited by 19
Applications of multiplexed CRISPR–Cas for genome engineering
Cheng, H., Jeong, E., & Cho, S. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01500-6 · Cited by 30
“Indeed, approval of CRISPR – Cas9 for the treatment of sickle cell disease by the US Food and Drug Administration proves that gene editing is not merely a research experiment; it is tangible reality 74 – 76 .”
Reinforced plant-derived lipid nanoparticles for oral precise epigenome editing in colonic diseases
Gao, Q., Gao, Y., Cao, Y., Xu, H., Ma, Y., Zu, M., Yang, Q., YANG, K. Y., Zhu, Z., Liu, C., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw9275 · Cited by 22
Materiomically Designed Polymeric Vehicles for Nucleic Acids: Quo Vadis?
Kumar, R. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00346 · Cited by 19
PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington’s disease
Shin, J. W., Hong, E. P., Park, S. S., Choi, D. E., Zeng, S., Chen, R. Z., & Lee, J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.005 · Cited by 24
Clinical trials and promising preclinical applications of CRISPR/Cas gene editing
Çerçi, B., Uzay, İ. A., Kara, M. K., & Dinçer, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121204 · Cited by 22
Optimization of CRISPR–Cas system for clinical cancer therapy
Meng, X. L., Wu, T., Lou, Q., Niu, K., Jiang, L., Xiao, Q., Xu, T., & Zhang, L. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10474 · Cited by 19
Park, S. H., Cao, M., & Bao, G. (2023) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2023.100478 · Cited by 24
Han, J. P., Lee, Y., Lee, J. H., Chung, H. Y., Lee, G. S., Nam, Y. R., Choi, M., Moon, K., Lee, H., Lee, H., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102050 · Cited by 19
“Intellia Therapeutics demonstrated the therapeutic potential of an in vivo KO strategy using CRISPR-Cas9 for Transthyretin amyloidosis 63 (ClinicalTrials.gov: NCT04601051).”
BackgroundControl of Selective mRNA Translation in Neuronal Subcellular Compartments in Health and Disease
Cagnetta, R., Flanagan, J. G., & Sonenberg, N. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.2240-22.2023 · Cited by 23
Jalil, S., Keskinen, T., Juutila, J., Sartori-Maldonado, R., Euro, L., Suomalainen, A., Lapatto, R., Kuuluvainen, E., Hietakangas, V., Otonkoski, T., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.03.004 · Cited by 20
“49,50 Our results suggest that LNPs are a highly promising tool for the editing of the ASL variant in the liver.”
Mitrani-Rosenbaum, S., Yakovlev, L., Becker‐Cohen, M., Argov, Z., Fellig, Y., & Harazi, A. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210755 · Cited by 21
Singh, K., Fronza, R., Evens, H., Chuah, M., & VandenDriessche, T. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101365 · Cited by 19
“4,5 Typically, CRISPR-Cas9-based gene editing results in a double-strand DNA break (DSB) at a speci fi c chromosomal locus, catalyzed by the Cas9 nuclease.”
The rise of cochlear gene therapy
Landegger, L. D., Reisinger, E., Lallemend, F., Hage, S. R., Grimm, D., & Cederroth, C. R. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.012 · Cited by 21
Nonviral targeted mRNA delivery: principles, progresses, and challenges
He, X., Li, G., Huang, L., Shi, H., Zhong, S., Zhao, S., Jiao, X., Xin, J., Yin, X., Liu, S., et al. (2025) · MedComm · doi:10.1002/mco2.70035 · Cited by 28
CRISPR Technology and Its Emerging Applications
Zhang, X. E., Ma, D., & Liu, F. (2025) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzaf034 · Cited by 23
“This approach was used to treat transthyretin amyloidosis caused by mutations in the TTR gene, and demonstrated a significant reduction in serum TTR levels in clinical trials [158].”
Patel, R., Ioannou, A., Sheikh, A., Razvi, Y., Mansell, J., Martinez-Naharro, A., Knight, D., Kotecha, T., Porcari, A., Chacko, L., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf412 · Cited by 14
Self-citationYashooa, R. K., Nabi, A. Q., Smail, S. W., Azeez, S. S., Nooh, W. A., Mustafa, S. A., Al-Farha, A. A.-B., Capitanio, N., & Shekha, M. S. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1737468 · Cited by 25
Polyrotaxane-based multi-step transformable materials for the delivery of Cas9 ribonucleoprotein
Taharabaru, T., Kihara, T., Onodera, R., Kogo, T., Higashi, K., Moribe, K., Nakamura, T., Motoyama, K., & Higashi, T. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101488 · Cited by 17
Highly specific chimeric DNA-RNA-guided genome editing with enhanced CRISPR-Cas12a system
Kim, H., Lee, W.-J., Kim, C. H., Oh, Y., Gwon, L. W., Lee, H. K., Song, W., Hur, J. K., Lim, K. S., Jeong, K. J., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.021 · Cited by 20
“Thus, it is easy to use the CRISPR-Cas system to access genetic diseases.(4,5) The field of gene therapy is growing into a large market in which these advanced genome-editing”
MethodAlameh, M., & Weissman, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00014-2 · Cited by 20
Advances in CRISPR/Cas gene therapy for inborn errors of immunity
Liu, X., Li, G., Liu, Y., Zhou, F., Huang, X., & Li, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111777 · Cited by 28
In vivo evaluation of guide-free Cas9-induced safety risks in a pig model
Ge, W., Gou, S., Zhao, X., Jin, Q., Zhuang, Z., Zhao, Y., Liang, Y., Ouyang, Z., Liu, X., Chen, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01905-1 · Cited by 19
“9,34,40 Therefore, we fi rst evaluated whether guide-free Cas9 could induce genomic damages in the PBMCs of our DIC pigs after Dox induction.”
Five Years of Progress in CRISPR Clinical Trials (2019–2024)
Davies, K., Philippidis, A., & Barrangou, R. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0081 · Cited by 17
Niu, X., Zhang, J., Zhang, J., Bai, L., Hu, S., Zhang, Z., & Bai, M. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c10032 · Cited by 22
Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles
Degtev, D., Bravo, J. P. K., Emmanouilidi, A., Zdravković, A., Choong, O. K., Touza, J. L., Selfjord, N., Weisheit, I., Francescatto, M., Akçakaya, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53418-8 · Cited by 22
RNA-based gene targeting therapies for human papillomavirus driven cancers
Salinas-Montalvo, A. M., Supramaniam, A., McMillan, N. A. J., & Idris, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.005 · Cited by 20
Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies
Cheng, M. H. Y., Brimacombe, C. A., Verbeke, R., & Cullis, P. R. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00365 · Cited by 19
A general genome editing strategy using CRISPR lipid nanoparticle spherical nucleic acids
Han, Z., Huang, C., Luo, T., & Mirkin, C. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426094122 · Cited by 17
“Lipid nanoparticles (LNPs) are promising nonviral alternatives ( 21 – 27 ) and have been employed in clinical trials ( 28 , 29 ), but their use for multiplexed cargo delivery is underexplored ( 30 ).”
In vivo liver targeted genome editing as therapeutic approach: progresses and challenges
Simoni, C., Barbon, E., Muro, A. F., & Cantore, A. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1458037 · Cited by 23
Kim, Y., Chatterjee, S., Robertson, A. L., Guerrero, E. D., Vaidya, A., Wang, X., Lee, S. M., Wei, J., Miller, W. E., Farbiak, L., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00282 · Cited by 21
Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo
Bykonya, A. G., Лавров, А. В., & Smirnikhina, S. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00479-z · Cited by 20
Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
Chamakioti, M., Karantzelis, N., & Taraviras, S. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094824 · Cited by 18
“Early-stage clinical trials of CRISPR-Cas9 are underway in blood disorders [23], cancers [24], eye diseases [25], and protein-folding disorders [26].”
BackgroundGaikwad, S., Phatak, P., & Mukherjee, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16027 · Cited by 15
Selvaraj, S., Claggett, B. L., Quarta, C. C., Yu, B., Inciardi, R. M., Buxbaum, J. N., Mosley, T. H., Shah, A. M., Dorbala, S., Falk, R. H., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1525 · Cited by 16
State-of-the-Art Document on Optimal Contemporary Management of Cardiomyopathies
Seferovic, P. M., Polovina, M. M., Rosano, G. M. C., Bozkurt, B., Metra, M., Heymans, S. R. B., Müllens, W., Bauersachs, J. K., Sliwa, K. S., de Boer, R. A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2979 · Cited by 19
Adams, D., Algalarrondo, V., & Echaniz‐Laguna, A. (2023) · Blood · doi:10.1182/blood.2023019884 · Cited by 19
Genome and transcriptome engineering by compact and versatile CRISPR-Cas systems
Aquino‐Jarquín, G. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103793 · Cited by 15
Cheng, Q., Farbiak, L., Vaidya, A., Guerrero, E. D., Lee, E. E., Rose, E. K., Wang, X., Robinson, J. J., Lee, S. M., Wei, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313009120 · Cited by 20
“…as a vaccine in the COVID - 19 pandemic via efficient delivery of mRNA encoding the SARS - CoV - 2 spike protein (10) to genome editing in humans with high efficacy and durability for hATTR (11–14), mRNA nanoparticles hold great promise as future medicines for a variety of diseases and cancer.”
Background
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



